|1.||Allbritton, Nancy L: 2 articles (02/2014 - 05/2013)|
|2.||Kovarik, Michelle L: 2 articles (02/2014 - 05/2013)|
|3.||Krige, David: 2 articles (05/2011 - 08/2008)|
|4.||Flores, Nicolas: 2 articles (10/2010 - 08/2008)|
|5.||Hooftman, Leon: 2 articles (10/2010 - 08/2009)|
|6.||Leszczynska, Katarzyna B: 1 article (09/2015)|
|7.||Hammond, Ester M: 1 article (09/2015)|
|8.||Anbalagan, Selvakumar: 1 article (09/2015)|
|9.||Biasoli, Deborah: 1 article (09/2015)|
|10.||Mukherjee, Somnath: 1 article (09/2015)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/01/2012 - "Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial."
04/01/2014 - "More recently, new generation aminopeptidase inhibitors became available, including the aminopeptidase inhibitor prodrug tosedostat, which is currently tested in phase II clinical trials for acute myeloid leukemia. "
02/01/2014 - "In this work, we examined the response of 678 individual U937 (human acute myeloid leukemia) cells to an aminopeptidase-inhibiting chemotherapeutic drug (Tosedostat) over the course of 95 days. "
02/01/2014 - "Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia."
05/21/2013 - "Using chemical cytometry, we measured peptide degradation in the U937 acute myeloid leukemia (AML) cell line in the presence and absence of the aminopeptidase inhibitor Tosedostat (CHR-2797). "
09/01/2015 - "To our knowledge, the effective combination of CHR-2797 with radiation exposure has not been reported previously in any cancer cell type. "
08/15/2008 - "It is suggested that aminopeptidase inhibitors, such as CHR-2797 and bestatin, deplete sensitive tumor cells of amino acids by blocking protein recycling, and this generates an antiproliferative effect. "
08/01/2009 - "A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors."
|3.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/01/2010 - "In phase II, the therapeutic activity of the maximum-acceptable dose (MAD) of tosedostat was evaluated in elderly and/or relapsing patients with acute myeloid leukemia (AML) or myelodysplastic syndrome. "
04/01/2013 - "Additional studies of tosedostat including combination with hypomethylating agents and low-dose cytarabine in patients with high-risk myelodysplastic syndromes and AML are ongoing or planned. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
|6.||N- (2- aminophenyl)- 4- ((4- pyridin- 3- ylpyrimidin- 2- ylamino)methyl)benzamide
|9.||acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamide